drugset / Trial / NCT04531865
Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment
Phase 3
Withdrawn
Children's Hospital of Fudan University
Shanghai Children's Hospital · collabShanghai Children's Medical Center · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to evaluate the efficacy and safety of maintenance Mycophenolate Mofetil following single course of Rituximab in maintaining remission over 12 months among Children with frequently-relapsing or steroid-dependent nephrotic syndrome
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-09-01
- Completion
- 2022-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mycophenolate Mofetil | Small molecule | 20 mg/kg | — |
| Subject | Mycophenolate Mofetil | Small molecule | 30 mg/kg | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |